Abstract
This review article deals with mitiglinide, a rapid-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients. Attention is drawn to the background history of mitiglinide, its chemistry, its determination in plasma, its metabolic pathway, preclinical investigations conducted – either in vitro on the uptake of mitiglinide by pancreatic islets, the effects of mitiglinide on ionic channels, its insulinotropic action and its effect on glucose metabolism in hepatocytes and its cardiovascular effects, or in vivo in animals – as well as to clinical investigations with mitiglinide.
Keywords::